Ask AI
Advances from EHA and ICML 2025

CME

Congress to Clinic: Expert Perspectives on Therapeutic Advances and Practice Changing Data Emerging From the 2025 EHA and ICML Congresses

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: March 24, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Aldoss I, Yoon JH, Barba P, et al. Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory C-cell acute lymphoblastic leukemia: Early results from the phase 1/2 SYRUS study. Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S117.
  2. Scarfò L, Parrondo RD, Thompson MC, et al. Updated efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the ongoing phase (ph) 1 CaDAnCe-101 study. Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S158.
  3. Matasar M, Li ZM, Vassilakopoulos TP, et al. Polatuzumab vedotin, rituximab, gemcitabine and oxaliplatin (Pola-R-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the randomized phase III POLARGO trial. Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S101.
  4. Dreyling M, Zinzani PL, Pavlovsky MA, et al. Efficacy of rituximab-bendamustine with or without acalabrutinib in patients with untreated, high-risk mantle cell lymphoma: An analysis of the phase 3 ECHO trial. Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S233.
  5. Trneny M, Luminari S, Scholz C, et al. Tafasitamab (tafa) plus lenalidomide (len) and rituximab (r) for patients with relapsed or refractory follicular lymphoma (R/R FL): results from the phase 3 inMIND study. Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S230.
  6. Song Y, Li ZM, Jim Z, et al. A pivotal study of SHR2554, an oral inhibitor against enhancer of zeste homolog 2 (EZH2), in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). Presented at: European Hematology Association Congress; June 12-15, 2025. Abstract S246.